Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications
Targeting CD30 in Malignant Tissues: Challenges in Detection and Clinical Applications
复制标题
靶向恶性组织中的 CD30：检测和临床应用的挑战
DOI：
--
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
D. Weisenburger
中科院分区：
文献类型：
--
作者：
M. Wasik;Gretchen S. Jimenez;D. Weisenburger
来自肿瘤坏死因子受体家族的CD30跨膜受体在不同的淋巴细胞增生性疾病和一小部分正常活化淋巴细胞中表达。因此，按照标准化方法正确检测CD30的表达，有助于对霍奇金淋巴瘤、间变性大细胞淋巴瘤等表达该受体的疾病的诊断。最近，CD30也成为一个有吸引力的治疗靶点。初步观察表明，目前用于检测CD30表达的方法，通常是在福尔马林固定、石蜡包埋的组织上进行免疫组织化学，在确定CD30作为治疗靶点方面可能不是最理想的，因为每个细胞只有有限数量的CD30受体分子可能足以达到治疗效果。
The CD30 transmembrane receptor from the tumor necrosis factor receptor family is expressed in a distinct, yet diverse set of lymphoproliferative disorders and a small subset of normal activated lymphocytes. Therefore, detection of CD30 expression when performed properly according to the standardized methods facilitates diagnosis of Hodgkin lymphoma, anaplastic large cell lymphoma, and other disorders expressing the receptor. More recently, CD30 has also become an attractive therapeutic target. The preliminary observations indicate that the methods currently used to detect CD30 expression, typically immunohistochemistry performed on formalin-fixed, paraffin-embedded tissues, may be suboptimal in regard to identifying CD30 as a therapeutic target since only a limited number of CD30 receptor molecules per cell may be sufficient to achieve therapeutic effect.